Experimental cell injection aims to heal painful anal fistulas
NCT ID NCT07557134
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 2 trial tests whether E-CEL UVEC Cells, a type of genetically engineered cell, can treat perianal fistula—a painful tunnel that forms near the anus. The treatment involves injecting the cells directly into the fistula tract in a minimally invasive procedure. Researchers will compare outcomes in 78 adults who receive the cells versus those who receive no treatment, looking for closure of the fistula and improvement in quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- E-CEL UVEC Cells (genetically engineered human umbilical vein endothelial cells)
- What this could lead to
- If successful, this could offer a new, minimally invasive treatment option for people with perianal fistula, potentially closing the tract and reducing pain and discharge.
- What could go wrong
- This is an early Phase 2 trial with only 78 participants, so results may not apply to everyone. The treatment is still experimental, and there is no guarantee it will work or be safe long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYPTOGLANDULAR PERIANAL FISTULA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New York Presbyterian/Weill Cornell Medical Center
New York, New York, 10028, United States